Efficacy of Oral Semaglutide after Switching from DPP-4 Inhibitors on Glucose Level and Body Weight Control in Japanese Type 2 Diabetes Patients with Obesity
Background and Objective: Although oral semaglutide may be considered as a suitable treatment option for obese patients with type 2 diabetes mellitus (T2DM) inadequately responsive to dipeptidyl peptidase (DPP)-4 inhibitor–based therapy, evidence from actual clinical settings remains limited. This study aimed to investigate the effect of oral semaglutide in obese patients with T2DM who had an inadequate response to DPP-4 inhibitor–based therapy. Methods: This study was a retrospective, single-center study in which outpatients with T2DM were 1) aged 20 years or older at the time of oral semaglutide administration, 2) treated with an existing DPP-4 inhibitor for 3 months and/or longer at the time of oral semaglutide administration, and 3) had a hemoglobin A1c (HbA1c) level of ≥ 6.5% and/or a body mass index (BMI) ≥ 25.0 kg/m2. The primary endpoints were changes in HbA1c and body weight from baseline to 6 months after oral semaglutide treatment switching from DPP-4 inhibitor. Results: In the 48 patients studied, HbA1c was 7.01 ± 0.54%, and BMI was 26.7 ± 3.6 kg/m2 at baseline. HbA1c significantly decreased by 0.68 ± 0.36%, and body weight significantly decreased by 3.4 ± 2.3 kg (p < 0.001 for each). Improvements in indices of lipid metabolism and liver function were observed. Non-serious nausea and loss of appetite were observed in many patients, but these symptoms resolved in approximately 3 months. Mild constipation was also observed. Conclusion: Oral semaglutide appears to be a promising alternative to DPP-4 inhibitors as a means of glycemic and weight control in obese T2DM.
References
[1]
McLean, B.A., Wong, C.K., Campbell, J.E., Hodson, D.J., Trapp, S. and Drucker, D.J. (2021) Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. EndocrineReviews, 42, 101-132. https://doi.org/10.1210/endrev/bnaa032
[2]
Andersen, A., Lund, A., Knop, F.K. and Vilsbøll, T. (2018) Glucagon-Like Peptide 1 in Health and Disease. NatureReviewsEndocrinology, 14, 390-403. https://doi.org/10.1038/s41574-018-0016-2
[3]
Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M. and Holst, J.J. (1996) Glucagon-Like Peptide 1 Undergoes Differential Tissue-Specific Metabolism in the Anesthetized Pig. AmericanJournalofPhysiology-EndocrinologyandMetabolism, 271, E458-E464. https://doi.org/10.1152/ajpendo.1996.271.3.e458
[4]
Ahrén, B., Landin-Olsson, M., Jansson, P., Svensson, M., Holmes, D. and Schweizer, A. (2004) Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. TheJournalofClinicalEndocrinology&Metabolism, 89, 2078-2084. https://doi.org/10.1210/jc.2003-031907
[5]
Herman, G.A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., et al. (2006) Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes. TheJournalofClinicalEndocrinology&Metabolism, 91, 4612-4619. https://doi.org/10.1210/jc.2006-1009
[6]
Craddy, P., Palin, H. and Johnson, K.I. (2014) Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. DiabetesTherapy, 5, 1-41. https://doi.org/10.1007/s13300-014-0061-3
[7]
Nauck, M.A., Vilsbøll, T., Gallwitz, B., Garber, A. and Madsbad, S. (2009) Incretin-based Therapies. DiabetesCare, 32, S223-S231. https://doi.org/10.2337/dc09-s315
[8]
Nauck, M.A., Niedereichholz, U., Ettler, R., Holst, J.J., Ørskov, C., Ritzel, R., et al. (1997) Glucagon-Like Peptide 1 Inhibition of Gastric Emptying Outweighs Its Insulinotropic Effects in Healthy Humans. AmericanJournalofPhysiology-EndocrinologyandMetabolism, 273, E981-E988. https://doi.org/10.1152/ajpendo.1997.273.5.e981
[9]
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C.B. and Flint, A. (2015) Semaglutide, a Once‐Weekly Human GLP‐1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel. TheJournalofClinicalPharmacology, 55, 497-504. https://doi.org/10.1002/jcph.443
[10]
Goldenberg, R.M. and Steen, O. (2019) Semaglutide: Review and Place in Therapy for Adults with Type 2 Diabetes. CanadianJournalofDiabetes, 43, 136-145. https://doi.org/10.1016/j.jcjd.2018.05.008
[11]
Aroda, V.R., Ahmann, A., Cariou, B., Chow, F., Davies, M.J., Jódar, E., et al. (2019) Comparative Efficacy, Safety, and Cardiovascular Outcomes with Once-Weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes: Insights from the SUSTAIN 1–7 Trials. Diabetes&Metabolism, 45, 409-418. https://doi.org/10.1016/j.diabet.2018.12.001
[12]
Buckley, S.T., Bækdal, T.A., Vegge, A., Maarbjerg, S.J., Pyke, C., Ahnfelt-Rønne, J., et al. (2018) Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist. ScienceTranslationalMedicine, 10, eaar7047. https://doi.org/10.1126/scitranslmed.aar7047
[13]
Rasmussen, M.F. (2020) The Development of Oral Semaglutide, an Oral GLP-1 Analog, for the Treatment of Type 2 Diabetes. DiabetologyInternational, 11, 76-86. https://doi.org/10.1007/s13340-019-00423-8
[14]
Thethi, T.K., Pratley, R. and Meier, J.J. (2020) Efficacy, Safety and Cardiovascular Outcomes of Once‐Daily Oral Semaglutide in Patients with Type 2 Diabetes: The PIONEER Programme. Diabetes, ObesityandMetabolism, 22, 1263-1277. https://doi.org/10.1111/dom.14054
[15]
Rosenstock, J., Allison, D., Birkenfeld, A.L., Blicher, T.M., Deenadayalan, S., Jacobsen, J.B., et al. (2019) Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea. JAMA, 321, 1466-1480. https://doi.org/10.1001/jama.2019.2942
[16]
Warnick, G.R., Knopp, R.H., Fitzpatrick, V. and Branson, L. (1990) Estimating Low-Density Lipoprotein Cholesterol by the Friedewald Equation Is Adequate for Classifying Patients on the Basis of Nationally Recommended Cutpoints. ClinicalChemistry, 36, 15-19. https://doi.org/10.1093/clinchem/36.1.15
[17]
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., et al. (2009) Revised Equations for Estimated GFR from Serum Creatinine in Japan. AmericanJournalofKidneyDiseases, 53, 982-992. https://doi.org/10.1053/j.ajkd.2008.12.034
[18]
Kanda, Y. (2012) Investigation of the Freely Available Easy-to-Use Software ‘EZR’ for Medical Statistics. BoneMarrowTransplantation, 48, 452-458. https://doi.org/10.1038/bmt.2012.244
[19]
Ministry of Health, Labor and Welfare and Ministry of Education, Culture, Sports, Science and Technology (2013) Ethical Guideline for Epidemiological Studies. http://www.mhlw.go.jp/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/dl/02-02.pdf
[20]
World Medical Association (2013) WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. https://www.wma.net//policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
[21]
Japan Diabetes Clinical Data Management Study Group (2021) Basic Tabulation Data in 2021 (in Japanese). http://jddm.jp/public-information/index-2021/
[22]
Davies, M.J., Aroda, V.R., Collins, B.S., Gabbay, R.A., Green, J., Maruthur, N.M., et al. (2022) Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). DiabetesCare, 45, 2753-2786. https://doi.org/10.2337/dci22-0034
[23]
Rosenthal, M., Arnold, A., Salkar, M., Patelb, S., Harrell, E., Aldridge, H., et al. (2022) Patient Centered Studies Focused on Type 2 Diabetes Management, Education, and Family Support: A Scoping Review. CurrentDiabetesReviews, 18, e171121197989. https://doi.org/10.2174/1573399818666211117113026
[24]
Nauck, M.A. and Meier, J.J. (2019) Pioneering Oral Peptide Therapy for Patients with Type 2 Diabetes. TheLancetDiabetes&Endocrinology, 7, 500-502. https://doi.org/10.1016/s2213-8587(19)30182-2
[25]
Pieber, T.R., Bode, B., Mertens, A., Cho, Y.M., Christiansen, E., Hertz, C.L., et al. (2019) Efficacy and Safety of Oral Semaglutide with Flexible Dose Adjustment versus Sitagliptin in Type 2 Diabetes (PIONEER 7): A Multicentre, Open-Label, Randomised, Phase 3a Trial. TheLancetDiabetes&Endocrinology, 7, 528-539. https://doi.org/10.1016/s2213-8587(19)30194-9
[26]
Rodbard, H.W., Rosenstock, J., Canani, L.H., Deerochanawong, C., Gumprecht, J., Lindberg, S.Ø., et al. (2019) Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. DiabetesCare, 42, 2272-2281. https://doi.org/10.2337/dc19-0883
[27]
Pratley, R., Amod, A., Hoff, S.T., Kadowaki, T., Lingvay, I., Nauck, M., et al. (2019) Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial. TheLancet, 394, 39-50. https://doi.org/10.1016/s0140-6736(19)31271-1
[28]
Overgaard, R.V., Hertz, C.L., Ingwersen, S.H., Navarria, A. and Drucker, D.J. (2021) Levels of Circulating Semaglutide Determine Reductions in HbA1c and Body Weight in People with Type 2 Diabetes. CellReportsMedicine, 2, Article 100387. https://doi.org/10.1016/j.xcrm.2021.100387
[29]
Okamoto, A., Yokokawa, H., Nagamine, T., Fukuda, H., Hisaoka, T. and Naito, T. (2021) Efficacy and Safety of Semaglutide in Glycemic Control, Body Weight Management, Lipid Profiles and Other Biomarkers among Obese Type 2 Diabetes Patients Initiated or Switched to Semaglutide from Other GLP-1 Receptor Agonists. JournalofDiabetes&MetabolicDisorders, 20, 2121-2128. https://doi.org/10.1007/s40200-021-00899-9
[30]
Furusawa, S., Nomoto, H., Yokoyama, H., Suzuki, Y., Tsuzuki, A., Takahashi, K., et al. (2023) Glycaemic Control Efficacy of Switching from Dipeptidyl Peptidase‐4 Inhibitors to Oral Semaglutide in Subjects with Type 2 Diabetes: A Multicentre, Prospective, Randomized, Open‐Label, Parallel‐Group Comparison Study (SWITCH‐SEMA 2 Study). Diabetes, ObesityandMetabolism, 26, 961-970. https://doi.org/10.1111/dom.15393
[31]
Yoneda, C., Kobayashi, J. and Kuribayashi, N. (2024) Efficacy and Safety of Switching from a Dipeptidyl Peptidase-4 Inhibitor to Oral Semaglutide in Japanese Patients with Type 2 Diabetes Mellitus. DiabetologyInternational, 15, 569-576. https://doi.org/10.1007/s13340-024-00734-5
